447 related articles for article (PubMed ID: 26318293)
1. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Huang RY; Eppolito C; Lele S; Shrikant P; Matsuzaki J; Odunsi K
Oncotarget; 2015 Sep; 6(29):27359-77. PubMed ID: 26318293
[TBL] [Abstract][Full Text] [Related]
2. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
3. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
6. The multi-specific V
Edwards CJ; Sette A; Cox C; Di Fiore B; Wyre C; Sydoruk D; Yadin D; Hayes P; Stelter S; Bartlett PD; Zuazo M; Garcia-Granda MJ; Benedetti G; Fiaska S; Birkett NR; Teng Y; Enever C; Arasanz H; Bocanegra A; Chocarro L; Fernandez G; Vera R; Archer B; Osuch I; Lewandowska M; Surani YM; Kochan G; Escors D; Legg J; Pierce AJ
Br J Cancer; 2022 May; 126(8):1168-1177. PubMed ID: 34969998
[TBL] [Abstract][Full Text] [Related]
7. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
[TBL] [Abstract][Full Text] [Related]
8. LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP; Marciscano AE; Drake CG; Vignali DA
Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
Andrews LP; Cillo AR; Karapetyan L; Kirkwood JM; Workman CJ; Vignali DAA
Clin Cancer Res; 2022 Dec; 28(23):5030-5039. PubMed ID: 35579997
[TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
11. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.
Bhagwat B; Cherwinski H; Sathe M; Seghezzi W; McClanahan TK; de Waal Malefyt R; Willingham A
J Immunol Methods; 2018 May; 456():7-14. PubMed ID: 29427592
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
13. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation.
Guy C; Mitrea DM; Chou PC; Temirov J; Vignali KM; Liu X; Zhang H; Kriwacki R; Bruchez MP; Watkins SC; Workman CJ; Vignali DAA
Nat Immunol; 2022 May; 23(5):757-767. PubMed ID: 35437325
[TBL] [Abstract][Full Text] [Related]
14. LAG3 (CD223) and autoimmunity: Emerging evidence.
Hu S; Liu X; Li T; Li Z; Hu F
J Autoimmun; 2020 Aug; 112():102504. PubMed ID: 32576412
[TBL] [Abstract][Full Text] [Related]
15. Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Nguyen LT; Ohashi PS
Nat Rev Immunol; 2015 Jan; 15(1):45-56. PubMed ID: 25534622
[TBL] [Abstract][Full Text] [Related]
16. Investigating combination benefit of PD1 and LAG3 co-blockade using an engineered cellular bioassay.
Bhagwat B; de Waal Malefyt R; Willingham A
Int Immunopharmacol; 2023 Jun; 119():109566. PubMed ID: 37044037
[TBL] [Abstract][Full Text] [Related]
17. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
Wierz M; Pierson S; Guyonnet L; Viry E; Lequeux A; Oudin A; Niclou SP; Ollert M; Berchem G; Janji B; Guérin C; Paggetti J; Moussay E
Blood; 2018 Apr; 131(14):1617-1621. PubMed ID: 29439955
[No Abstract] [Full Text] [Related]
18. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
[TBL] [Abstract][Full Text] [Related]
19. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
[TBL] [Abstract][Full Text] [Related]
20. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]